For citizens

For companies

For medical specialists

EMA to further clarify safety profile of human papillomavirus (HPV) vaccines

The Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of HPV vaccines to further clarify aspects of their safety profile. Like all medicines the safety of these vaccines is monitored by the PRAC. The review will look at available data with a focus on rare reports of two conditions: complex regional pain syndrome and postural orthostatic tachycardia syndrome. The review does not question that the benefits of HPV vaccines outweigh their risks.

More information:

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2015